For instance, SLC16A1 is significantly upregulated in diffuse large B-cell lymphoma (DLBCL) and downregulated in AML, while the opposite is true for SLC16A3. Moreover, the expression of SLC16A1 and SLC16A3 is negatively correlated on a pan-cancer and AML-specific level (Fig. 7c–e), indicating that in a subset of cancer patients the expression pattern of these MCTs is divergent and suggestive of eligibility for AZD3965 therapy or other inhibitors specific for one of the two transporters. The gene discussed is SLC16A1; the disease is acute myeloid leukemia.